Keloid treatment: Is there a role for acellular human dermis (Alloderm)?

SummaryBackgroundKeloid management is faced with high recurrence rates. Keloid fibroblasts lack the normal negative feedback mechanism resulting in an exuberant scar formation. Alloderm® doesn't undergo the same proliferative process as keloidal scar dermis.ObjectiveTo evaluate Alloderm as a treatment modality for keloidsMethodsA retrospective chart review of six patients with a total of eight large recurrent keloids was performed. Patients were treated with excision of the keloid followed by placement of Alloderm. Each patient was evaluated for recurrence and complications.ResultsDuring follow-up ranging from 1 month to 4½ years there were 0% recurrences. Two out of 8 (25%) had residual induration. one of the two patients with residual induration, required an intralesional injection of kenalog at 6 months post-op.ConclusionOur results from this small study show that with the use of Alloderm after keloid excision, recurrence is low. Further study is warranted.